Evidence map›Paper›PMID 27682873›Full record

ArticleOncotarget2017

Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation.

Suraj Peri, Elena Caretti, Rossella Tricarico, Karthik Devarajan, Mitchell Cheung, Eleonora Sementino, Craig W Menges, Emmanuelle Nicolas, Lisa A Vanderveer, Sharon Howard and 16 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. The two-hit theory hits 50.Molecular biology of the cell · 2021
    Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Comparative Expression Profiling of Wild TypeFrontiers in physiology · 2019
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 1 country.

Suraj PeriDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Elena CarettiCancer Epigenetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Rossella TricaricoCancer Epigenetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Karthik DevarajanDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Mitchell CheungCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Eleonora SementinoCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Craig W MengesCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Emmanuelle NicolasCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Lisa A VanderveerCancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, USA.
Sharon HowardBlood Cell Development and Function, Fox Chase Cancer Center, Philadelphia, PA, USA.
Peggy ConradUniversity of California San Francisco, San Francisco, CA, USA.
James A CrowellDevelopmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, MD, USA.
Kerry S CampbellBlood Cell Development and Function, Fox Chase Cancer Center, Philadelphia, PA, USA.
Eric A RossDepartment of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Andrew K GodwinDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Anthony T YeungCancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, USA.
Margie L ClapperCancer Prevention and Control, Fox Chase Cancer Center, Philadelphia, PA, USA.
Robert G UzzoCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Elizabeth P HenskeBrigham and Women's Hospital, Harvard Medical School, Boston, MA, NCI, Bethesda, MD, USA.
Christopher J RickettsUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.
Cathy D VockeUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute Bethesda, MD, USA.
Joseph R TestaCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Alfonso BellacosaCancer Epigenetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
Levy KopelovichDepartment of Medicine, Weill Cornell Medical College, New York, NY, USA.
Alfred G KnudsonCancer Biology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Fox Chase Cancer Center · USNational Cancer Institute · USBrigham and Women's Hospital · USCenter for Cancer Research · USCornell University · USUniversity of California, San Francisco · USUniversity of Kansas Medical Center · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase GeneZIABC011038 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$29.8M
Tissue ProcessingSequencing FacilityZICBC011044 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI VOCKE, CATHY D · 2009 to 2025
$13.5M
PHASE I STUDIES OF CHEMOPREVENTIVE AGENTS, WORKSTATEMENTN01CN095037 · CN · FOX CHASE CANCER CENTER · PI KNUDSON, ALFRED G · 1999 to 2000
$975k
PHASE I STUDIES OF CHEMOPREVENTIVE AGENTS, WORKSTATEMENT 37-261995037N01CA095037 · NCI · FOX CHASE CANCER CENTER · 2002 to 2002
–
NCI NIH HHS N01 CN095037NCI NIH HHS P30 CA006927
6 · The paper itself

Abstract

Tumor suppressor genes and their effector pathways have been identified for many dominantly heritable cancers, enabling efforts to intervene early in the course of disease. Our approach on the subject of early intervention was to investigate gene expression patterns of morphologically normal "one-hit" cells before they become hemizygous or homozygous for the inherited mutant gene which is usually required for tumor formation. Here, we studied histologically non-transformed renal epithelial cells from patients with inherited disorders that predispose to renal tumors, including von Hippel-Lindau (VHL) disease and Tuberous Sclerosis (TSC). As controls, we studied histologically normal cells from non-cancerous renal epithelium of patients with sporadic clear cell renal cell carcinoma (ccRCC). Gene expression analyses of VHLmut/wt or TSC1/2mut/wt versus wild-type (WT) cells revealed transcriptomic alterations previously implicated in the transition to precancerous renal lesions. For example, the gene expression changes in VHLmut/wt cells were consistent with activation of the hypoxia response, associated, in part, with the "Warburg effect". Knockdown of any remaining VHL mRNA using shRNA induced secondary expression changes, such as activation of NFκB and interferon pathways, that are fundamentally important in the development of RCC. We posit that this is a general pattern of hereditary cancer predisposition, wherein haploinsufficiency for VHL or TSC1/2, or potentially other tumor susceptibility genes, is sufficient to promote development of early lesions, while cancer results from inactivation of the remaining normal allele. The gene expression changes identified here are related to the metabolic basis of renal cancer and may constitute suitable targets for early intervention.

Indexed as

Calcium-Binding ProteinsCarcinoma, Renal CellCell Line, TumorGene Expression ProfilingGene Knockdown TechniquesGenetic Predisposition to DiseaseHaploinsufficiencyHeterozygoteHumansImmunoblottingKidney NeoplasmsMutationOligonucleotide Array Sequence AnalysisReal-Time Polymerase Chain ReactionTranscriptomeVon Hippel-Lindau Tumor Suppressor ProteinCalcium-Binding ProteinsTESC protein, humanVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteinprimary kidney epithelial cellstranscriptomicsTSC1TSC2VHL

Identifiers

PMID27682873
PMCPMC5392274
OpenAlexW2521606025

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.